Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...

Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...

The majority of people with psoriatic arthritis first experience skin symptoms. One of the most common is a rash with thick, discolored skin covered with flaky, lighter-colored patches.

Libtayo (cemiplimab). The supply agreement supports the evaluation of Immuneering’s lead product candidate, IMM-1-104, in combination with Libtayo in patients with unresectable or metastatic RAS ...

Libtayo (cemiplimab). The supply agreement supports the evaluation of Immuneering’s lead product candidate, IMM-1-104, in combination with Libtayo in patients with unresectable or metastatic ...

Polymorphic light eruption (PMLE), commonly known as a sun rash or sun poisoning, is a type of photodermatosis triggered by an immune system reaction to the sun's ultraviolet (UV) radiation. Not ...

Adult diaper rash can develop when wearing adult diapers, incontinence briefs, or pads. It typically begins as small, inflamed patches of irritated skin and progresses to larger patches of raised ...

However, as it progresses, it can cause symptoms such as itchy skin, pruritus, and a rash. Around 35.5 million adults in the United States live with kidney disease, but only about 10% know they ...

Skin biopsy: To do this, your dermatologist removes a small sample from your rash, so that it can be examined under a microscope. Nail biopsy: If lichen planus may be affecting one or more of your ...

Rash during pregnancy is not uncommon, ranging from a relatively harmless heat rash to potentially life-threatening conditions like impetigo herpetiformis. These rashes may develop due to changes in ...

Adjuvant cemiplimab demonstrated a statistically significant improvement in DFS compared to placebo in post-surgical patients with high-risk CSCC, impacting post-operative care considerations.

Cemiplimab is under clinical development by Regeneron Pharmaceuticals and currently in Phase II for Hepatocellular Carcinoma. According to GlobalData, Phase II drugs for Hepatocellular Carcinoma have ...